Announced Thu, 3 Sept, 2026 · 14:28 IST
ESG rating rises to 65 from 64 for FY26
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.0%1-day move
₹213.91
prior close
₹213.72
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+0.0+2.6+5.7+2.1-0.9-5.0-1.9-9.0——
Up moveDown movePending
AI summary
Piramal Pharma's ESG rating improved to 65 for FY 2025-26 from 64 last year, per NSE Sustainability Ratings and Analytics. The rating was prepared voluntarily by NSE based on publicly available ESG data; it was not commissioned by the company.
Likely market impact
Small one-point ESG score improvement. Limited direct impact on stock price; reflects steady sustainability practices.